AnnJi Pharmaceutical Co., Ltd. (TPEX:7754)
Taiwan
· Delayed Price · Currency is TWD 45.85
-0.45 (-0.97%)
At close: Dec 5, 2025
AnnJi Pharmaceutical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 23.85 | 96.45 | 143.53 | 1.63 | 1.44 |
| Revenue Growth (YoY) | -86.90% | -32.80% | 8727.18% | 13.31% | - |
| Cost of Revenue | 23.38 | 87.56 | 125.09 | 0.51 | 0.46 |
| Gross Profit | 0.47 | 8.89 | 18.44 | 1.12 | 0.98 |
| Selling, General & Admin | 29.43 | 47.54 | 39.92 | 18.18 | 18.83 |
| Research & Development | 311.22 | 321.49 | 247.15 | 223.43 | 184.42 |
| Operating Expenses | 340.66 | 369.03 | 287.07 | 241.61 | 203.25 |
| Operating Income | -340.19 | -360.14 | -268.62 | -240.5 | -202.28 |
| Interest Expense | -1.69 | -1.78 | -0.47 | -0.03 | -0.15 |
| Interest & Investment Income | 8.29 | 9.37 | 5.84 | 1.69 | 0.19 |
| Currency Exchange Gain (Loss) | 17.57 | 2.78 | 1.51 | 0.04 | -0.53 |
| Other Non Operating Income (Expenses) | 0.49 | 0.25 | 0.18 | 3.83 | 4.12 |
| EBT Excluding Unusual Items | -315.54 | -349.53 | -261.56 | -234.98 | -198.65 |
| Gain (Loss) on Sale of Investments | -1.68 | -4.54 | -29.42 | -0.42 | - |
| Gain (Loss) on Sale of Assets | 0.09 | 0.09 | 0.2 | 0.34 | - |
| Other Unusual Items | - | - | - | - | 0.01 |
| Pretax Income | -317.13 | -353.99 | -290.78 | -235.06 | -198.64 |
| Income Tax Expense | - | - | 38.44 | 1.59 | -0.01 |
| Net Income | -317.13 | -353.99 | -329.22 | -236.65 | -198.63 |
| Net Income to Common | -317.13 | -353.99 | -329.22 | -236.65 | -198.63 |
| Shares Outstanding (Basic) | 94 | 93 | 77 | 66 | 45 |
| Shares Outstanding (Diluted) | 94 | 93 | 77 | 66 | 45 |
| Shares Change (YoY) | 3.49% | 20.01% | 17.96% | 45.17% | - |
| EPS (Basic) | -3.38 | -3.81 | -4.25 | -3.61 | -4.39 |
| EPS (Diluted) | -3.38 | -3.81 | -4.25 | -3.61 | -4.39 |
| Free Cash Flow | -294.12 | -195.97 | -79.23 | -191.07 | -143.62 |
| Free Cash Flow Per Share | -3.14 | -2.11 | -1.02 | -2.91 | -3.18 |
| Gross Margin | 1.96% | 9.22% | 12.85% | 68.57% | 68.01% |
| Operating Margin | -1426.24% | -373.40% | -187.15% | -14790.59% | -14095.82% |
| Profit Margin | -1329.58% | -367.02% | -229.37% | -14554.12% | -13841.46% |
| Free Cash Flow Margin | -1233.09% | -203.18% | -55.20% | -11750.92% | -10008.22% |
| EBITDA | -302.46 | -322.53 | -232.55 | -203.21 | -164.04 |
| EBITDA Margin | - | - | -162.02% | - | - |
| D&A For EBITDA | 37.73 | 37.61 | 36.07 | 37.29 | 38.24 |
| EBIT | -340.19 | -360.14 | -268.62 | -240.5 | -202.28 |
| EBIT Margin | - | - | -187.15% | - | - |
Source: S&P Capital IQ. Standard template. Financial Sources.